AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

60.50USD
27 Feb 2015
Change (% chg)

$-0.02 (-0.03%)
Prev Close
$60.52
Open
$60.53
Day's High
$60.99
Day's Low
$60.37
Volume
8,649,052
Avg. Vol
9,597,357
52-wk High
$70.76
52-wk Low
$45.50

ABBV.K

Chart for ABBV.K

About

AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company’s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease, and complications associated with... (more)

Overall

Beta: --
Market Cap(Mil.): $96,621.42
Shares Outstanding(Mil.): 1,593.89
Dividend: 0.51
Yield (%): 3.37

Financials

  ABBV.K Industry Sector
P/E (TTM): 55.19 38.99 40.21
EPS (TTM): 1.10 -- --
ROI: 9.22 17.01 16.34
ROE: 56.91 17.53 17.27
Search Stocks

Promising data bodes well for all-Achillion hep C treatment

- Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.

09 Feb 2015

UPDATE 2-Promising data bodes well for all-Achillion hep C treatment

* Study shows Achillion's inhibitor looks best-in-class: analyst

09 Feb 2015

Catamaran backs Gilead's hepatitis C treatment over AbbVie competitor

- Pharmacy benefit manager Catamaran Corp said on Tuesday that it will back Gilead Sciences Inc's Harvoni and Sovaldi as exclusive hepatitis C treatments on its drug coverage lists.

03 Feb 2015

Catamaran backs Gilead's hepatitis C treatment over AbbVie competitor

Feb 3 - Pharmacy benefit manager Catamaran Corp said on Tuesday that it will back Gilead Sciences Inc's Harvoni and Sovaldi as exclusive hepatitis C treatments on its drug coverage lists.

03 Feb 2015

UPDATE 2-AbbVie expects hep C drug sales to top $3 billion per year

Jan 30 - AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences .

30 Jan 2015

Drugmaker AbbVie beats estimates as Humira sales rise

- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

30 Jan 2015

AbbVie expects more than $3 billion in annual hepatitis C drug sales

- AbbVie Inc's chief executive said on Friday the company's new hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences .

30 Jan 2015

AbbVie says it will take meaningful share of hepatitis C market

Jan 30 - AbbVie Inc's top executive said on Friday that the company's new hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences Inc .

30 Jan 2015

UPDATE 1-Drugmaker AbbVie beats estimates as Humira sales rise

Jan 30 - U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

30 Jan 2015

AbbVie profit beats estimates on higher Humira sales

Jan 30 - U.S. drugmaker AbbVie Inc reported a better-than-expected quarterly adjusted profit due to higher sales of its autoimmune disease drug Humira.

30 Jan 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $102.51 -0.29
Pfizer Inc. (PFE.N) $34.32 -0.27
Novartis AG (NOVN.VX) CHF97.45 -0.70
Merck & Co., Inc. (MRK.N) $58.54 -0.42
Roche Holding Ltd. (ROG.VX) CHF258.80 -0.20
Abbott Laboratories (ABT.N) $47.37 -0.24
Eli Lilly and Co (LLY.N) $70.17 +0.14

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Validea
$12.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks